Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Canadian Cancer Trials Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
PETHEMA Foundation
The Children's Hospital of Zhejiang University School of Medicine
University of Miami
Sun Yat-sen University
Hackensack Meridian Health
Karyopharm Therapeutics Inc
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Memorial Sloan Kettering Cancer Center
Karyopharm Therapeutics Inc
Tianjin Medical University Cancer Institute and Hospital
Duke University
The First Affiliated Hospital with Nanjing Medical University
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Second Affiliated Hospital of Soochow University
Institute of Hematology & Blood Diseases Hospital, China
Odense University Hospital
University Health Network, Toronto
University of Rochester
Antengene Corporation
US Oncology Research
Ruijin Hospital
Peking Union Medical College Hospital
Academic and Community Cancer Research United
Ruijin Hospital
Ruijin Hospital
Karyopharm Therapeutics Inc
Washington University School of Medicine
Loyola University
University of Leeds
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Karyopharm Therapeutics Inc
Weill Medical College of Cornell University
The First Affiliated Hospital of Soochow University
Antengene Corporation
Shanghai Tong Ren Hospital
Shanghai Changzheng Hospital
Georgetown University
The First Affiliated Hospital of Soochow University
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc